Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Item
http://www.wikidata.org/entity/Q44189727
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphomaFludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.Role of fludarabine in hematological malignancies.Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsMyelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaFludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removalProspective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.Management of indolent lymphoma: where are we now and where are we going.Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.Follicular lymphoma: current management and future directions.Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.Irinotecan (CPT-11) in the treatment of mycosis fungoides.Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies.
P2860

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Item
http://www.wikidata.org/entity/Q44189727
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@en
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@nl
type
label
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@en
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@nl
prefLabel
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@en
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Fludarabine, mitoxantrone, dex ...... th stage IV indolent lymphoma.
@en
P2093
P304
P31
P356
10.1182/BLOOD-2001-12-0269
P407
P433
P478
P50
P577
P5875
P698
P921